Logo

Singapore's first clinical trial approval for T cell engineere...

SINGAPORE, Aug. 20, 2018 /PRNewswire-AsiaNet/ -- Lion TCR Pte. Ltd., a Singapore-based Biotech company receives approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multicentre clinical study of its product candidate (LioCyx(TM)) for treatment of relapsed liver cancer pos...

Read more http://asianetnews.net/view-release?pr-id=74802

Asian Spectator by NewsServices.com - office@NewsServices.com - 1300 660 660